NFE2L2 and Alzheimer disease: Compounds that activate Nrf2 (Table 3), such as sulforaphane and dimethyl fumarate, have shown promise in preclinical models, and some are even in clinical trials for other neurodegenerative diseases, providing evidence of their potential to treat AD (Table 3).